158 related articles for article (PubMed ID: 35378827)
1. NRF3 Decreases during Melanoma Carcinogenesis and Is an Independent Prognostic Marker in Melanoma.
Immonen A; Haapasaari KM; Skarp S; Karihtala P; Teppo HR
Oxid Med Cell Longev; 2022; 2022():2240223. PubMed ID: 35378827
[TBL] [Abstract][Full Text] [Related]
2. NRF1 and NRF2 mRNA and Protein Expression Decrease Early during Melanoma Carcinogenesis: An Insight into Survival and MicroRNAs.
Hämäläinen M; Teppo HR; Skarp S; Haapasaari KM; Porvari K; Vuopala K; Kietzmann T; Karihtala P
Oxid Med Cell Longev; 2019; 2019():2647068. PubMed ID: 31687076
[TBL] [Abstract][Full Text] [Related]
3. Association of galectin-3 expression with melanoma progression and prognosis.
Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
[TBL] [Abstract][Full Text] [Related]
4. Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma.
Gacević M; Jović M; Zolotarevski L; Stanojević I; Novaković M; Miller K; Šuljagić V; Mijušković Ž; Vojvodić D
Vojnosanit Pregl; 2016 May; 73(5):449-57. PubMed ID: 27430109
[TBL] [Abstract][Full Text] [Related]
5. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
7. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.
Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G
Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007
[TBL] [Abstract][Full Text] [Related]
8. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker.
Maeda A; Aragane Y; Tezuka T
Br J Dermatol; 1998 Aug; 139(2):198-206. PubMed ID: 9767232
[TBL] [Abstract][Full Text] [Related]
10. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients.
Weinlich G; Bitterlich W; Mayr V; Fritsch PO; Zelger B
Br J Dermatol; 2003 Sep; 149(3):535-41. PubMed ID: 14510986
[TBL] [Abstract][Full Text] [Related]
11. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.
Li J; Cheng Y; Tai D; Martinka M; Welch DR; Li G
Oncogene; 2011 Feb; 30(8):896-906. PubMed ID: 20935672
[TBL] [Abstract][Full Text] [Related]
13. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
14. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis.
Kaddu S; Smolle J; Zenahlik P; Hofmann-Wellenhof R; Kerl H
Melanoma Res; 2002 Jun; 12(3):271-8. PubMed ID: 12140384
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.
Rangel J; Torabian S; Shaikh L; Nosrati M; Baehner FL; Haqq C; Leong SP; Miller JR; Sagebiel RW; Kashani-Sabet M
J Clin Oncol; 2006 Oct; 24(28):4565-9. PubMed ID: 17008696
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of redox-state-regulating enzymes in melanocytic skin tumours and the surrounding microenvironment.
Hintsala HR; Soini Y; Haapasaari KM; Karihtala P
Histopathology; 2015 Sep; 67(3):348-57. PubMed ID: 25627040
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
[TBL] [Abstract][Full Text] [Related]
18. Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation.
Fox C; Lambie D; Wilmott JS; Pinder A; Pavey S; Lê Cao KA; Akalin T; Karaarslan IK; Ozdemir F; Scolyer RA; Yamada M; Soyer HP; Schaider H; Gabrielli B
Pigment Cell Melanoma Res; 2016 Jul; 29(4):444-52. PubMed ID: 27166757
[TBL] [Abstract][Full Text] [Related]
19. Expression of SOX10, ABCB5 and CD271 in melanocytic lesions and correlation with survival data of patients with melanoma.
Gambichler T; Petig AL; Stockfleth E; Stücker M
Clin Exp Dermatol; 2016 Oct; 41(7):709-16. PubMed ID: 27663144
[TBL] [Abstract][Full Text] [Related]
20. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
